One of the more common side effects of chemotherapy is anemia, or the lack of hemoglobin (red blood cells). Severe anemia is dangerous and will require the suspension of the use of chemotherapy as well as immediate treatment. In light of this the U.S. Food and Drug Administration (FDA) has required that Amgen Inc. developed [...]
Everyone who reads this blog regularly knows that I am a passionate advocate for increased funding in the fight against cancer, especially prostate cancer. However, sometimes it is a good idea to push back from the table and evaluate the true nature of a situation. The Harris poll has published a recent survey which concluded [...]
Can brachytherapy be a reasonable salvage option for men with a local recurrence after the failure of initial radiotherapy for prostate cancer treatment? A recent review of the literature evaluated the use of radiation as a salvage option after the failure of local-only treatment with radiation. The results were mixed. The researchers did a PubMed [...]
On September 27th Dendreon announced that it has enrolled and started its first patient with metastatic advanced prostate cancer that is castrate resistanr in a European Union based clinical trial of Provenge. Finally, men in the EU can hope that in the near future that Provenge could become available to them. The trial is hoped [...]
Spinal cord compression is not an uncommon occurrence in men with advanced prostate cancer. Bones are the most common target of advanced prostate cancer, including the spine. Sadly, there is often a delay in diagnosing spinal cord compression resulting from prostate cancer. These delays in diagnosis can influence the eventual functional outcome. Oncologists, primary care [...]